Immutep Limited - American Depositary Shares (IMMP)
IMMP moved a median of -0.42% 30 minutes after news, and -0.45% by the close. How IMMP actually reacts to news — the realized, point-in-time move the market made, measured across 494 labeled events over the last three years with zero look-ahead.
IMMP’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | -0.26% | 39% | 477 |
| 30-min | -0.42% | 42% | 492 |
| 60-min | -0.27% | 45% | 493 |
| to close | -0.45% | 45% | 491 |
| Middle 50% of IMMP reactions | -2.11% to +1.46% |
|---|---|
| Median reaction (30-min) | -0.42% |
| Measured reactions | 494 |
Half of all Immutep Limited - American Depositary Shares news events land between -2.11% and +1.46% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
Email me when IMMP moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to IMMP's baseline. Nothing else.
Recent IMMP events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Immutep Regains Compliance with Nasdaq Minimum Bid Price Requirement | Press release | GlobeNewswire | +2.78% | -0.83% | |
| Immutep Receives ~A$0.86 Million R&D Tax Incentive | Press release | GlobeNewswire | +0.00% | -2.92% | |
| Form 6-K IMMUTEP Ltd For: Sep 21 | SEC filing · Form 6-K | SEC EDGAR | -2.00% | -4.29% | |
| Change to American Depositary Share Ratio | Press release | GlobeNewswire | +0.18% | +3.67% | |
| Form 6-K IMMUTEP Ltd For: Sep 11 | SEC filing · Form 6-K | SEC EDGAR | -3.15% | -5.13% | |
| Immutep Outlines Focused Development Strategy for Eftilagimod Alfa (“efti”) | Press release | GlobeNewswire | +6.94% | +1.58% | |
| Form 6-K IMMUTEP Ltd For: Aug 31 | SEC filing · Form 6-K | SEC EDGAR | -1.72% | +1.56% | |
| Form 6-K IMMUTEP Ltd For: Jul 30 | SEC filing · Form 6-K | SEC EDGAR | +1.62% | +4.39% | |
| Immutep Quarterly Activities Report Q4 FY26 | Press release | GlobeNewswire | -0.03% | +2.62% | |
| Immutep Announces Abstract Accepted for Presentation at the European Society for Medical Oncology (ESMO) Congress 2026 | Press release | GlobeNewswire | +3.26% | -0.39% | |
| Form 6-K IMMUTEP Ltd For: Jul 13 | SEC filing · Form 6-K | SEC EDGAR | -4.14% | -5.71% | |
| Immutep Secures Fourth United States Patent for Eftilagimod Alfa in Combination with a PD-1 Pathway Inhibitor | Press release | GlobeNewswire | -4.14% | -5.71% | |
| Immutep Provides Clinical Update in 1st line NSCLC: Positive Mature Overall Survival Data from INSIGHT-003 and Update from TACTI-004 | Press release | GlobeNewswire | +3.20% | +6.88% | |
| Immutep Limited Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - IMMP | Press release | PR Newswire | +0.07% | -0.94% | |
| Immutep Limited Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - IMMP | Press release | PR Newswire | +2.01% | +6.62% | |
| Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against ImmunityBio, Inc. (IMMP) and Encourages Shareholders to Learn More About the Investigation | Press release | ACCESS Newswire | +2.01% | +6.62% | |
| Immutep Limited Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - IMMP | Press release | PR Newswire | +1.33% | +9.04% | |
| Bronstein, Gewirtz & Grossman, LLC Encourages ImmunityBio, Inc. (IMMP) Shareholders to Inquire about Securities Investigation | Press release | ACCESS Newswire | — | +4.30% | |
| Immutep Limited Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - IMMP | Press release | PR Newswire | +1.47% | +0.80% | |
| Bronstein, Gewirtz & Grossman, LLC Is Investigating ImmunityBio, Inc. (IMMP) And Encourages Shareholders to Connect | Press release | ACCESS Newswire | +1.47% | +0.80% | |
| Bronstein, Gewirtz & Grossman, LLC Encourages ImmunityBio, Inc. (IMMP) Stockholders to Inquire about Securities Investigation | Press release | ACCESS Newswire | +0.32% | -0.29% | |
| Immutep Limited Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - IMMP | Press release | PR Newswire | +3.97% | +4.31% | |
| ImmunityBio, Inc. (IMMP) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation | Press release | ACCESS Newswire | +3.97% | +4.31% | |
| Immutep Limited Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - IMMP | Press release | PR Newswire | -0.06% | +2.53% | |
| Bronstein, Gewirtz & Grossman, LLC Encourages ImmunityBio, Inc. (IMMP) Stockholders to Inquire about Securities Investigation | Press release | ACCESS Newswire | +0.15% | +1.91% | |
| Immutep Limited Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - IMMP | Press release | PR Newswire | -2.34% | -3.96% | |
| ImmunityBio, Inc. (IMMP) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation | Press release | ACCESS Newswire | -2.34% | -3.96% | |
| Form 6-K IMMUTEP Ltd For: Jun 04 | SEC filing · Form 6-K | SEC EDGAR | -0.39% | -3.44% | |
| Immutep Limited Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - IMMP | Press release | PR Newswire | -0.39% | -3.44% | |
| Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against ImmunityBio, Inc. (IMMP) and Encourages Stockholders to Learn More About the Investigation | Press release | ACCESS Newswire | — | -1.97% | |
| Immutep to Present Positive Interim Phase I Data for IMP761, a First-in-Class LAG-3 Agonist Antibody, at EULAR 2026 | Press release | GlobeNewswire | -2.85% | -4.64% | |
| Immutep Limited Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - IMMP | Press release | PR Newswire | -1.93% | -2.00% | |
| Bronstein, Gewirtz & Grossman, LLC Encourages ImmunityBio, Inc. (IMMP) Investors to Inquire about Securities Investigation | Press release | ACCESS Newswire | -1.96% | +0.51% | |
| Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against ImmunityBio, Inc. (IMMP) And Encourages Stockholders to Reach Out | Press release | ACCESS Newswire | +1.45% | +2.09% | |
| Systemic immune activation with eftilagimod alfa associated with statistically significant increased overall survival in late-stage cancer patients | Press release | GlobeNewswire | -0.34% | -0.65% | |
| Immutep Quarterly Activities Report Q3 FY26 | Press release | GlobeNewswire | +0.15% | -2.69% | |
| Immutep Receives Nasdaq Notice of Bid Price Deficiency | Press release | GlobeNewswire | +0.15% | -2.69% | |
| Immutep Announces Abstract Accepted for Presentation at the American Society of Clinical Oncology (ASCO) 2026 Annual Meeting | Press release | GlobeNewswire | +0.61% | +0.41% | |
| Immutep Receives FDA Orphan Drug Designation for Eftilagimod Alfa in Soft Tissue Sarcoma | Press release | GlobeNewswire | -3.35% | -45.05% | |
| Immutep Reports Progress from Phase I Study of LAG-3 Agonist for Autoimmune Diseases | Press release | GlobeNewswire | -3.49% | -0.58% | |
| Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Immutep Limited (IMMP) And Encourages Stockholders to Reach Out | Press release | ACCESS Newswire | -0.12% | -0.15% | |
| TACTI-004 Phase III Study in First Line NSCLC to be discontinued following Futility Analysis | Press release | GlobeNewswire | -10.89% | -11.89% | |
| Immutep Achieves 50% Enrolment in Global TACTI-004 (KEYNOTE-F91) Phase III Trial in 1L NSCLC | Press release | GlobeNewswire | +0.19% | -1.13% | |
| Immutep Quarterly Activities Report Q2 FY26 | Press release | GlobeNewswire | +0.00% | -2.30% | |
| Immutep Announces Positive Update on IMP761, a First-in-Class LAG-3 Agonist Antibody for Autoimmune Diseases, from Phase I Study | Press release | GlobeNewswire | -2.92% | +0.73% | |
| Immutep Announces Strong Operational Progress in Global TACTI-004 (KEYNOTE-F91) Phase III and Enrolment Continues at Robust Pace | Press release | GlobeNewswire | +4.08% | +1.63% | |
| Immutep and Dr. Reddy’s enters into Strategic Collaboration for Commercialisation of an Innovative Oncology Drug, Eftilagimod Alfa | Press release | GlobeNewswire | +5.50% | +13.50% | |
| Immutep to Present New Data from AIPAC-003 Phase II at the 2025 San Antonio Breast Cancer Symposium | Press release | GlobeNewswire | -2.13% | -2.13% | |
| Translational Data and Significant Pathologic Response Rates from EFTISARC-NEO Phase II Highlighted in Oral Presentation at CTOS 2025 | Press release | GlobeNewswire | +1.69% | — | |
| Immutep Receives A$4.6 million R&D Tax Incentive from French Government | Press release | GlobeNewswire | +0.00% | -3.17% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the IMMP section they belong to.
Where else IMMP is measured.
IMMP earnings → · Analyst actions → · SEC filings →
Other Healthcare names, measured the same way
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| VolitionRX Limited (VNRX) | 498 | -0.05% | 41% |
| ANI Pharmaceuticals, Inc. (ANIP) | 496 | -0.05% | 46% |
| FOAMIX PHARMACEUTICALS LTD (FOMX) | 493 | -0.29% | 41% |
| AzurRx BioPharma, Inc. (AZRX) | 492 | -0.24% | 36% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not.
All Healthcare names, measured the same way →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Immutep Limited - American Depositary Shares's median reaction calculated?
Every labeled IMMP news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 494 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 42% of IMMP's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does IMMP's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.